Preventing Colo-rectal Cancer

Keeping your POOP Healthy

Basic Definition

Colorectal cancer refers to cancers arising in either the colon or the rectum; they are often grouped together because they share many biological and clinical features. The colon is the main part of the large intestine, and the rectum is the final segment that connects the colon to the anus.

Most cases begin as small, benign growths called adenomatous polyps in the inner lining of the colon or rectum, which can accumulate mutations over years and transform into invasive cancer (the adenoma–carcinoma sequence). At the cellular level, colorectal cancer typically starts in epithelial cells and is driven by genetic and epigenetic changes affecting pathways such as Wnt/β‑catenin, MAPK/ERK, PI3K/AKT/mTOR, and TGF‑β, which promote uncontrolled growth, survival, and invasion.

Figure 1. Stages of Colorectal cancer

Symptoms and clinical impact

Early colorectal cancer may cause no symptoms at all; when present, symptoms can include changes in bowel habits (diarrhea, constipation, or stool narrowing), blood in the stool, abdominal pain, fatigue, and unexplained weight loss. It is one of the most common cancers worldwide and can cause severe illness and premature death, especially when diagnosed at an advanced stage.

Why screening matters

Because the polyp‑to‑cancer progression is usually slow, screening tests such as colonoscopy can detect and remove precancerous polyps or find cancers at an early, more curable stage.

What is the Cause of Colorectal Cancer

Colorectal cancer does not usually have one single “cause”; it develops when multiple inherited and environmental risk factors converge and drive malignant transformation of colonic or rectal epithelium.(1)

Non‑modifiable causes (background risk)

• Ageing: Risk rises sharply after about age 50, although incidence in younger adults has been increasing.

• Family history of colorectal cancer or advanced adenomatous polyps, especially in a first‑degree relative or at a young age in the family.

• Inherited cancer syndromes such as Lynch syndrome (HNPCC) and familial adenomatous polyposis (FAP), which confer very high lifetime risk.(1)

• Long‑standing inflammatory bowel disease (ulcerative colitis, Crohn’s colitis), which markedly increases colorectal cancer risk via chronic inflammation–dysplasia–carcinoma pathways.(1)

Lifestyle and metabolic causes (modifiable)

• Dietary pattern: High intake of red and processed meat, charred/grilled meat, high‑fat and low‑fiber diets, and low intake of fruits and vegetables all increased risk.(1)

• Obesity and physical inactivity: Excess body weight and low physical activity are consistently associated with higher colorectal cancer incidence and mortality.

• Tobacco and alcohol: Cigarette smoking and heavy alcohol use (2–4 or more drinks daily) are established colorectal carcinogens.(1)

• Type 2 diabetes and insulin resistance: These are associated with higher risk, partly overlapping with obesity and inactivity.

Prognosis

Prognosis in colorectal cancer depends strongly on how far the tumor has spread at diagnosis; earlier stages have high cure rates, while metastatic disease has much lower long‑term survival. (2)

Prognosis by AJCC TNM stage (illustrative ranges)

• Stage I colon cancer: 5‑year survival around 90% or slightly higher.​(2)

• Stage II: survival varies by T stage but is often in the 65–85% range overall.​

• Stage III: with modern multimodality therapy, many series report 5‑year survival around 50–75%, with better outcomes for stage IIIA than IIIC.​

• Stage IV: 5‑year survival is typically around 10–15%, though selected patients with limited metastases (e.g., resectable liver or lung lesions) can do substantially better

How to reduce the risk of colorectal cancer

You can lower your risk of colorectal cancer by combining regular screening with lifestyle changes and, in some cases, preventive medicines.

1. Get screened and remove polyps

• Regular screening (such as colonoscopy, stool tests, or sigmoidoscopy) can find and remove precancerous polyps before they turn into cancer, making it one of the most effective prevention strategies.(3)

• Most guidelines recommend that average‑risk adults start screening in mid‑life (often around age 45) and earlier if there is a strong family history or genetic syndrome.

• See post “Colonoscopy Versus Flexible Sigmoidoscopy for Colorectal Cancer Screening: An Evidence-Based Review“

2. Optimize weight, activity, and smoking/alcohol

• Maintain a healthy body weight and avoid obesity; excess weight and weight gain in adulthood are linked to higher colorectal cancer risk.(3)

• Engage in regular moderate to vigorous physical activity (aim for at least 30–60 minutes on most days), which lowers risk by improving insulin sensitivity, reducing inflammation, and supporting gut motility.

• Avoid tobacco completely and limit or avoid alcohol, since both smoking and heavier drinking meaningfully increase colorectal cancer risk.(3)

3. Improve diet quality

• Emphasize vegetables, fruits, whole grains, and other plant foods that provide fiber and protective phytochemicals, which support a healthier gut environment and may dilute or neutralize carcinogens in the colon.(3)

• Limit red meat (beef, pork, lamb) and especially processed meats (bacon, sausage, deli meats, hot dogs), which are consistently associated with increased colorectal cancer risk.

• Prefer cooking methods that avoid heavy charring or burning of meat, and reduce sugary, highly processed foods that contribute to obesity and metabolic dysfunction.

4. Increase intake of dietary fiber

• Non‑digestible fiber reaches the colon and is fermented by microbiota to short‑chain fatty acids, especially butyrate, which can promote cancer cell cycle arrest and apoptosis, inhibit inflammation, and act as a histone deacetylase inhibitor.(4)

• A high‑fiber diet is consistently associated with a modestly lower risk of colorectal cancer, likely via multiple mechanisms in the colon and microbiome.(5)

• A pooled analysis found about a 10% lower colorectal cancer risk for each 10 g/day higher total or cereal fiber intake, and roughly 17–20% lower risk with three extra daily servings of whole grains.

• Highest versus lowest fiber intake groups had 14% lower proximal colon cancer risk and 21% lower distal colon cancer risk.(6)

• An umbrella review of diet and colorectal cancer reported “convincing” evidence that higher dietary fiber intake is associated with reduced colorectal cancer incidence.(7)

Question: The Maasai and traditional Inuit have a low fiber intake yet have a very low risk of colorectal cancer.

The experiences of the Maasai and traditional Inuit are consistent with the idea that colorectal cancer is influenced by an interplay of factors rather than fiber alone. Their diets were low in fiber but were also characterized by: very low intake of refined sugars and starches, low circulating insulin, absence of ultra-processed foods, high levels of physical activity, low rates of obesity and metabolic syndrome. These observations suggest that metabolic health, chronic inflammation, and dietary quality as a whole may be at least as important as fiber intake. At the same time, they do not demonstrate that fiber has no role. Rather, they highlight the difficulty of attributing differences in colorectal cancer risk to a single dietary component when entire lifestyles differ. In other words, the Maasai and traditional Inuit challenge an overly simplistic "fiber deficiency causes colon cancer" hypothesis, but they do not refute evidence that fiber can contribute to colorectal health within the broader context of diet and lifestyle.

5. Manage high‑risk conditions and family history

• If you have inflammatory bowel disease (ulcerative colitis or Crohn’s colitis) or a hereditary syndrome (e.g., Lynch syndrome, FAP), you may need earlier and more frequent colonoscopic surveillance and, in some cases, prophylactic surgery.

• People with a strong family history of colorectal cancer or advanced polyps should discuss personalized screening intervals and preventive strategies with a gastroenterologist or genetics professional.

Repurpose Drugs and Nutraceuticals to Prevent Colorectal Cancer

Several repurposed drugs and nutraceuticals have reasonably good human or strong preclinical evidence for lowering colorectal neoplasia risk, though very few are guideline‑endorsed for average‑risk primary prevention.

Repurposed drugs with human data

• Aspirin (low–moderate dose)

  • Multiple randomized adenoma‑prevention trials show that daily aspirin (81–325 mg) reduces recurrence of colorectal adenomas, with somewhat stronger effects on advanced lesions.​(3, 8)

  • In Lynch syndrome, 600 mg/day for ≥2 years reduced long‑term colorectal cancer incidence by about 40% on extended follow‑up.(9) Based on the recently completed CaPP3 trial a dose of 75-100 mg/day is currently recommended (Lancet Gastroenterol Hepatol 2026).

  • Intermittent dosing schedules (e.g., 3 weeks on/3 weeks off) can modulate colorectal carcinogenesis biomarkers, suggesting potential to retain activity with fewer adverse effects.​(10)

  • Bleeding and GI risk make this a shared decision tool, not a blanket recommendation.

• Metformin

  • A large meta‑analysis of 37 studies (≈1.4 million participants with diabetes) found metformin users had ~20% lower risk of colorectal neoplasms (hazard ratio 0.79; odds ratio 0.80).(11)

  • Cohort data suggest long‑term use (≥5 years) and higher cumulative dose correlate with lower colorectal cancer risk and better survival in diabetics.(12)

  • Evidence in non‑diabetics is limited; currently best supported as a chemo-preventive candidate in people who already need metformin for metabolic disease.

Vitamins and Nutraceuticals with colorectal‑focused data

• Vitamin D

  • A recent meta-analysis of 17 cohorts comprising 5,706 CRC cases and 7,107 controls with a wide range of serum 25(OH)D levels shows that deficiency of 25(OH)D (< 20 ng/mL) is associated with a 31% higher CRC risk (relative risk [RR], 1.31; 95% CI, 1.05–1.62), and that sufficiency (30–35 or 35–40 ng/mL) is associated with 19% (RR, 0.81; 95% CI, 0.67–0.99) and 27% (RR, 0.73; 95% CI, 0.59–0.91) lower risk.(13)

  • Another meta-analysis of 30 studies from 1989 to 2019 also indicates a negative association between serum 25(OH)D levels and CRC risk (RR, 0.68; 95% CI, 0.60–0.78). (14)

  • Higher blood vitamin D levels are consistently associated with lower colorectal cancer risk. It is claimed that randomized trials of vitamin D pills have not yet proven that supplementation by itself prevents colorectal cancer; however, these trial are absurdly underpowered or used an absurdly low dose of vitamin D (400 IU or 1000 IU /day); i.e. they were designed to fail.

  • A study of whether Vitamin D prevents colorectal adenomas examined 2,259 participants recently diagnosed with adenoma within the previous 4 months; patients were randomly assigned to receive daily calcium (1,200 mg) and Vitamin D3 (1,000 IU) or placebo. A follow-up colonoscopy was performed 3 or 5 years after the index colonoscopy. No difference was found between the groups... Duh. (15)

  • WHI Calcium + Vitamin D Trial (postmenopausal women). 36,282 women randomized to 1000 mg calcium + 400 IU vitamin D3 daily vs placebo for 7 years.​ No significant difference in invasive colorectal cancer incidence (HR 1.08, 95% CI 0.86–1.34. Duh, Duh.

  • High‑dose versus standard‑dose vitamin D3 added to chemotherapy in metastatic colorectal cancer improved progression‑free survival in the phase 2 SUNSHINE study, but this is treatment of existing cancer, not primary prevention.(16)

How to interpret this data

• Higher physiological 25(OH)D levels (e.g., from sun exposure, diet, and/or supplements) is likely protective against colorectal cancer.

• Taking vitamin D is reasonable to correct deficiency and to achieve adequate Vitamin D3 blood levels (40-60 pg/ml) and this will likely contribute to risk reduction, but it should be considered an adjunct to screening, diet, and lifestyle rather than a stand‑alone chemopreventive drug.

• Curcumin

  • Demonstrates chemopreventive and cytotoxic activity against colorectal cancer cells via NF‑κB, AP‑1, EGFR, and Wnt/β‑catenin pathway modulation.(17)

  • In rodent models, curcumin reduces aberrant crypt foci (ACF), macroscopic tumors, and neoplastic lesions in the colon.(18)

  • Human pilot work (in high‑risk patients) suggests ACF reduction and favorable mucosal biomarker changes, but large, definitive prevention trials are still lacking.(19)

• Sulforaphane (cruciferous vegetables / concentrated extracts)

  • In vitro and animal models show inhibition of colon cancer cell viability, proliferation, angiogenesis, and significant reductions in ACF and tumor burden.​(18, 19)

  • Acts via Nrf2 activation, HDAC inhibition, and modulation of phase II detox enzymes; epidemiology linking crucifer intake to lower CRC risk is supportive but not definitive.(19)

• Polyphenol combinations (curcumin + sulforaphane)

  • In colon cancer cell lines, combinations of curcumin and sulforaphane show synergistic reductions in viability, with relative sparing of normal colon cells, supporting a multi‑nutraceutical strategy targeting complementary pathways.(18)

• Green tea (EGCG)

  • Green tea and EGCG have clear anticancer activity against colorectal cells, but human data so far suggest at most a modest, not definitively proven, prevention effect for colorectal neoplasia.

Human evidence

• A large Japanese RCT in patients with prior colorectal adenomas tested green tea extract (300 mg EGCG/day) versus placebo for 3 years; adenoma recurrence was slightly lower with green tea (about 4–5% absolute difference) but this was not statistically significant overall.(20)

• Epidemiologic data show that higher green tea intake is associated with lower risk of gastric and colon cancers in some cohorts, but results are inconsistent and confounded by lifestyle factors.(20)

• For a risk‑reduction stack, regular green‑tea consumption or a standardized EGCG supplement could be considered an adjunct with plausible benefit and low toxicity in most people, rather than a stand‑alone preventive.(21)

• Omega 3- fatty acids

  • Omega‑3 fatty acids have plausible anticancer mechanisms and some supportive observational data. (22)

  • Preclinical work shows omega‑3s can reduce colon tumor growth and adenoma burden, and trials of high‑dose EPA in patients with prior colorectal cancer suggest potential in preventing recurrent adenomas.(23)

  • Some cohort studies link higher intake of fish‑derived DHA and marine omega‑3s with modestly lower colorectal or rectal cancer risk. (22, 23)

Practical takeaway

Eating fish and having adequate marine omega‑3 intake is reasonable for general health and may offer some colorectal benefit.

Resveratrol

• Resveratrol has strong mechanistic and animal data suggesting chemopreventive potential in colorectal cancer, but human evidence is still early

  • Resveratrol targets multiple colorectal carcinogenesis pathways, including Wnt/β‑catenin, LEF1/MYC, NF‑κB, IGF‑1/Akt, apoptosis, autophagy, oxidative stress, EMT, and angiogenesis, leading to reduced proliferation, increased apoptosis, and decreased invasiveness of colon cancer cells.(24)

  • In rodent and organoid models, resveratrol reduces aberrant crypt foci and adenoma number, tumor burden, and progression, and in connectivity‑map–guided screening it was identified as the most effective chemopreventive compound against colorectal adenomas among 1309 FDA‑approved agent(25)

  • Small clinical studies in patients with colorectal cancer show that oral resveratrol (around 0.5–1 g/day) achieves measurable levels of active metabolites in colorectal tissue and can significantly reduce tumor cell proliferation indices, supporting biological activity in human colon mucosa. (26)

Practical interpretation

Resveratrol is best viewed as a promising adjunctive nutraceutical with multi‑targeted anticancer mechanisms and robust preclinical support for colorectal chemoprevention, but it is not at the same evidence level as aspirin for human prevention outcomes.

Table 1. Role of various compounds in reducing risk of colorectal cancer

Practical positioning and caveats

• None of these agents replaces colonoscopy or guideline‑based screening, which remains the most powerful preventive tool via polypectomy.

• Aspirin has the strongest human outcome data, especially in high‑risk groups, but carries non‑trivial bleeding risk; metformin’s signal is robust in diabetics but not yet practice‑changing for non‑diabetics.

• Curcumin and sulforaphane sit at the “promising but not yet guideline‑level” stage: strong mechanistic and animal data, small human biomarker studies, but no large primary‑prevention RCTs with cancer endpoints.

Figure 2. Preventing Colorectal Cancer

New Here?

Start with the: Cancer and the Metabolic Library

Medical Disclaimer: The discussion of repurposed medications and nutraceuticals in this article is intended to review the scientific literature and does not constitute a recommendation for self-treatment. Decisions regarding the use of off-label therapies should be made in consultation with a qualified healthcare professional familiar with the patient’s medical history and current treatment plan. Please see the full Medical Disclaimer on the introductory page to Marik’s Cancer & Metabolic Healing Playbook.

References

1. Lewandowska A, Rudzki G, Lewandowski T, Stryjkowska-Góra A, Rudzki S. Risk Factors for the Diagnosis of Colorectal Cancer. Cancer Control. 2022;29:10732748211056692.

2. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89–103.

3. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology. 2010;138(6):2029–43.e10.

4. Zeng H, Lazarova DL, Bordonaro M. Mechanisms linking dietary fiber, gut microbiota and colon cancer prevention. World J Gastrointest Oncol. 2014;6(2):41–51.

5. Aune D, Chan DS, Lau R, Vieira R, Greenwood DC, Kampman E, et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. Bmj. 2011;343:d6617.

6. Ma Y, Hu M, Zhou L, Ling S, Li Y, Kong B, et al. Dietary fiber intake and risks of proximal and distal colon cancers: A meta-analysis. Medicine (Baltimore). 2018;97(36):e11678.

7. Veettil SK, Wong TY, Loo YS, Playdon MC, Lai NM, Giovannucci EL, et al. Role of Diet in Colorectal Cancer Incidence: Umbrella Review of Meta-analyses of Prospective Observational Studies. JAMA Netw Open. 2021;4(2):e2037341.

8. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101(4):256–66.

9. Burn J, Sheth H, Elliott F, Reed L, Macrae F, Mecklin JP, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet. 2020;395(10240):1855–63.

10. Zhu X, Chen R, Ness RM, Naik RD, Murff HJ, Zhang H, et al. Evaluating Intermittent Dosing of Aspirin for Colorectal Cancer Chemoprevention. Cancer Prev Res (Phila). 2025;18(6):321–34.

11. Shen M, Lu S, Xu Z, Zhou F, Sheng LT, Yu Q. Metformin for primary prevention of colorectal neoplasms in adenoma-free populations: a systematic review and dose-response meta-analysis. Front Pharmacol. 2025;16:1645387.

12. Bradley MC, Ferrara A, Achacoso N, Ehrlich SF, Quesenberry CP, Jr., Habel LA. A Cohort Study of Metformin and Colorectal Cancer Risk among Patients with Diabetes Mellitus. Cancer Epidemiol Biomarkers Prev. 2018;27(5):525–30.

13. McCullough ML, Zoltick ES, Weinstein SJ, Fedirko V, Wang M, Cook NR, et al. Circulating Vitamin D and Colorectal Cancer Risk: An International Pooling Project of 17 Cohorts. J Natl Cancer Inst. 2019;111(2):158–69.

14. Huang D, Lei S, Wu Y, Weng M, Zhou Y, Xu J, et al. Additively protective effects of vitamin D and calcium against colorectal adenoma incidence, malignant transformation and progression: A systematic review and meta-analysis. Clin Nutr. 2020;39(8):2525–38.

15. Baron JA, Barry EL, Mott LA, Rees JR, Sandler RS, Snover DC, et al. A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. N Engl J Med. 2015;373(16):1519–30.

16. Ng K, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, et al. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. Jama. 2019;321(14):1370–9.

17. Ojo OA, Adeyemo TR, Rotimi D, Batiha GE, Mostafa-Hedeab G, Iyobhebhe ME, et al. Anticancer Properties of Curcumin Against Colorectal Cancer: A Review. Front Oncol. 2022;12:881641.

18. Santana-Gálvez J, Villela-Castrejón J, Serna-Saldívar SO, Cisneros-Zevallos L, Jacobo-Velázquez DA. Synergistic Combinations of Curcumin, Sulforaphane, and Dihydrocaffeic Acid against Human Colon Cancer Cells. Int J Mol Sci. 2020;21(9).

19. Islam MR, Akash S, Rahman MM, Nowrin FT, Akter T, Shohag S, et al. Colon cancer and colorectal cancer: Prevention and treatment by potential natural products. Chem Biol Interact. 2022;368:110170.

20. Stingl JC, Ettrich T, Muche R, Wiedom M, Brockmöller J, Seeringer A, et al. Protocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population. BMC Cancer. 2011;11:360.

21. Noman AM, Sultan MT, Mazhar A, Baig I, Javaid J, Hussain M, et al. Anticancer Molecular Mechanisms of Epigallocatechin Gallate: An Updated Review on Clinical Trials. Food Sci Nutr. 2025;13(8):e70735.

22. Kantor ED, Lampe JW, Peters U, Vaughan TL, White E. Long-chain omega-3 polyunsaturated fatty acid intake and risk of colorectal cancer. Nutr Cancer. 2014;66(4):716–27.

23. Vasudevan A, Yu Y, Banerjee S, Woods J, Farhana L, Rajendra SG, et al. Omega-3 fatty acid is a potential preventive agent for recurrent colon cancer. Cancer Prev Res (Phila). 2014;7(11):1138–48.

24. Honari M, Shafabakhsh R, Reiter RJ, Mirzaei H, Asemi Z. Resveratrol is a promising agent for colorectal cancer prevention and treatment: focus on molecular mechanisms. Cancer Cell Int. 2019;19:180.

25. Wada H, Sato Y, Fujimoto S, Okamoto K, Bando M, Kawaguchi T, et al. Resveratrol inhibits development of colorectal adenoma via suppression of LEF1; comprehensive analysis with connectivity map. Cancer Sci. 2022;113(12):4374–84.

26. Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol. 2017;1.